Maravai LifeSciences (NASDAQ:MRVI) Given “Market Perform” Rating at William Blair

William Blair reiterated their market perform rating on shares of Maravai LifeSciences (NASDAQ:MRVI) in a research note released on Friday, MarketBeat Ratings reports.

Other research analysts also recently issued reports about the stock. Morgan Stanley downgraded shares of Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $11.00 to $10.00 in a research report on Tuesday, August 13th. UBS Group upped their price target on Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. Wells Fargo & Company began coverage on shares of Maravai LifeSciences in a research note on Tuesday, August 27th. They set an “overweight” rating and a $10.00 price objective on the stock. The Goldman Sachs Group lowered their target price on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, October 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $15.00 price target on shares of Maravai LifeSciences in a report on Friday, August 16th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Maravai LifeSciences presently has an average rating of “Moderate Buy” and a consensus price target of $10.33.

Maravai LifeSciences Stock Performance

NASDAQ MRVI opened at $5.78 on Friday. Maravai LifeSciences has a 1-year low of $4.68 and a 1-year high of $11.56. The company has a 50 day moving average of $8.03 and a 200-day moving average of $8.49. The company has a current ratio of 10.00, a quick ratio of 9.28 and a debt-to-equity ratio of 0.71. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -3.52 and a beta of 0.02.

Institutional Trading of Maravai LifeSciences

A number of institutional investors have recently modified their holdings of MRVI. GAMMA Investing LLC raised its position in Maravai LifeSciences by 310.2% in the 2nd quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock valued at $26,000 after buying an additional 2,711 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Maravai LifeSciences in the second quarter valued at approximately $32,000. Headlands Technologies LLC bought a new stake in shares of Maravai LifeSciences in the first quarter worth $42,000. Blue Trust Inc. acquired a new position in Maravai LifeSciences during the second quarter worth $44,000. Finally, Venturi Wealth Management LLC bought a new position in Maravai LifeSciences in the third quarter valued at $47,000. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.